2256 Stock Overview
Engages in the discovering and developing small molecule oncology therapies in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Abbisko Cayman Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$6.50 |
| 52 Week High | HK$6.46 |
| 52 Week Low | HK$2.35 |
| Beta | 1.29 |
| 1 Month Change | 35.98% |
| 3 Month Change | 55.50% |
| 1 Year Change | 155.91% |
| 3 Year Change | 25.00% |
| 5 Year Change | n/a |
| Change since IPO | -47.58% |
Recent News & Updates
Recent updates
Companies Like Abbisko Cayman (HKG:2256) Can Afford To Invest In Growth
Sep 30
Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation
Apr 27An Intrinsic Calculation For Abbisko Cayman Limited (HKG:2256) Suggests It's 37% Undervalued
Jan 09Will Abbisko Cayman (HKG:2256) Spend Its Cash Wisely?
Nov 01We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth
Jun 08Shareholder Returns
| 2256 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 30.3% | 11.7% | 3.2% |
| 1Y | 155.9% | 18.9% | 23.6% |
Return vs Industry: 2256 exceeded the Hong Kong Biotechs industry which returned 18.9% over the past year.
Return vs Market: 2256 exceeded the Hong Kong Market which returned 23.6% over the past year.
Price Volatility
| 2256 volatility | |
|---|---|
| 2256 Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 13.9% |
| 10% least volatile stocks in HK Market | 3.1% |
Stable Share Price: 2256 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2256's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 275 | Yao-Chang Xu | www.abbisko.com |
Abbisko Cayman Limited engages in the discovering and developing small molecule oncology therapies in China. The company develops pimicotinib, which is in Phase III clinical trial for treatment of tenosynovial giant cell tumor; Irpagratinib that is in Phase II clinical trial for treatment of liver cancer; Fexagratinib, which is in Phase II clinical trial for the treatment of urothelial carcinoma; ABSK043 that is in Phase I clinical trial for treatment of multiple tumors; ABSK061, ABSK121, and ABSK051, which is in Phase I clinical trial for treatment of solid tumors; ABSK112 that is in Phase I of clinical trial for treatment of non-small cell lung cancer; ABSK012, which is in Phase I clinical trial for treatment of soft tissue sarcoma. It is involved in technical services and consultation.
Abbisko Cayman Limited Fundamentals Summary
| 2256 fundamental statistics | |
|---|---|
| Market cap | HK$3.96b |
| Earnings (TTM) | -HK$17.37m |
| Revenue (TTM) | HK$533.26m |
7.6x
P/S Ratio-233.9x
P/E RatioIs 2256 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2256 income statement (TTM) | |
|---|---|
| Revenue | CN¥497.27m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥497.27m |
| Other Expenses | CN¥513.47m |
| Earnings | -CN¥16.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 03, 2025
| Earnings per share (EPS) | -0.026 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3.26% |
| Debt/Equity Ratio | 0% |
How did 2256 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 16:14 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abbisko Cayman Limited is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |
| null null | China International Capital Corporation Limited |